Lars Henrik Jensen - Concepedia

Author

Lars Henrik Jensen

Also Known As

Jensen, L. H., Jensen, Lars H, Jensen, Lars Henrik, L H Hentze Jensen, L Jensen, L. H. Jensen, L. Henrik Jensen, L. Jensen, L.H. Jensen, L.M.B. Jensen

287

Publications

7.7K

Citations

H-Index

Concepts

All Affiliations

Vejle Sygehus University of Southern Denmark Region of Southern Denmark Sorbonne Université National Cancer Center Hospital East

About

Lars Henrik Jensen is an author at Vejle Sygehus specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	28	2.6K
2	Health Sciences	8	8	866
3	Education	1	1	25
4	Nursing	1	1	41
5	Public Health	1	1	15

Lars Henrik Jensen

Publications

7.1K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer Thierry André, Kai‐Keen Shiu, Tae Won Kim, New England Journal of Medicine	2020	2.8K
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study Luis A. Díaz, Kai‐Keen Shiu, Tae‐Won Kim, The Lancet Oncology MedicineImmunologyPathologyColorectal CancerPembrolizumab Versus Chemotherapy	2022	818
High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study Ane Appelt, John Pløen, Henrik Harling, The Lancet Oncology Surgical OncologyRadiation TherapyGastrointestinal OncologyMedicineDistal Rectal Cancer	2015	539
Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial Alexander Stein, Dirk Arnold, John Bridgewater, BMC Cancer	2015	226
Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial Thierry André, Mayur M. Amonkar, Josephine M. Norquist, The Lancet Oncology Health-related QualityMedicineCancer ManagementColorectal CancerPathology	2021	211
Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study. Thierry André, Kai‐Keen Shiu, Tae Won Kim, Journal of Clinical Oncology ImmunologyPathologyLba4 BackgroundKeynote-177 StudyOncology	2020	196
Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer Thierry André, Elena Élez, Eric Van Cutsem, New England Journal of Medicine	2024	158
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial Thierry André, Elena Élez, Heinz‐Josef Lenz, The Lancet MedicineColorectal CancerPathologyImmune Checkpoint InhibitorIpilimumab Versus Nivolumab	2025	115
Neoadjuvant chemotherapy in locally advanced colon cancer.<b>A phase II trial</b> Anders Jakobsen, Fahimeh Andersen, Anders Fischer, Acta Oncologica	2015	110
Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer Lars Henrik Jensen, Jan Lindebjerg, Torben Frøstrup Hansen, Annals of Oncology Gastrointestinal OncologyMedicineBiliary CancerPathologyBiliary Disorder	2012	108

Page 1